Long-acting HIV treatment: latest news

Long-acting HIV treatment news from aidsmap

More news

Long-acting HIV treatment news selected from other sources

  • Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

    Now that long-acting antiretroviral therapy (LA-ART) is nearly a reality, is it something that people with HIV will prefer over once-daily pills? A study presented during a poster session at the International Conference on HIV Treatment and Prevention Adherence tried to find out whether LA-ART was as acceptable as daily-pill ART among 374 people living with HIV in a clinic in Houston. While they found that overall, LA-ART was acceptable among a majority of people, it wasn't equally acceptable among all groups.

    7 hours ago | The Body Pro
  • NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

    A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.

    09 May 2019 | National Institute of Allergy and Infectious Diseases
  • ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

    If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV

    29 April 2019 | ViiV press release
  • Long-Acting HIV Treatment Is Coming. Our Health Care System Needs to Prepare

    New conversations are starting in HIV care as phase III trials have shown that monthly injections of cabotegravir and rilpivirine (Edurant) are non-inferior to a three-drug pill regimen. In 2018, TheBody asked a range of people living with HIV about their willingness to switch to an injectible, and most had mixed feelings. But even if there's widespread interest in this new way of taking antiretroviral therapy (and most likely also prevention, not too far away), it's important to consider not just the willingness of people to move to this new form of treatment, but whether health care systems and providers in the U.S. are ready to support this innovation.

    16 April 2019 | The Body Pro
  • Jose Arribas, MD, on the Challenges That Come With Long-Acting Injectables

    The announcement of the results of the FLAIR and ATLAS studies at the Annual Conference on Retroviruses and Opportunistic Infections in March was a major step forward in the field of long-acting injectables for the treatment and management of HIV. But with advances come challenges.

    15 April 2019 | Contagion Live
  • Laura Waters, MD, FRCP: Can Two Drugs Tango?

    In a symposium presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019), Laura Waters, MD, FRCP, discussed the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered. Contagion® sat down with Dr. Waters for an exclusive interview about her presentation and to discuss new data from several studies presented at the meeting.

    12 March 2019 | Contagion Live
  • Long-acting injectible antiretroviral trial begins

    Can a monthly injection of two antiretroviral drugs offer a better chance of suppressing the virus than current oral regimens, among individuals with adherence challenges? A trial that will enroll some 350 volunteers with documented lapses in treatment in the preceding year and a half will seek to find out, the National Institutes of Health announced today.

    28 February 2019 | Science Speaks
  • Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

    Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

    30 January 2019 | Positively Aware
  • ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

    The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.

    05 November 2018 | Poz
  • Long-lasting HIV injection is a step closer after second GSK study

    A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients to be filed with regulators.

    31 October 2018 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.